Question 3: How is patient progress in opioid agonist treatment monitored?
Answer: Patient progress should be monitored via clinical evaluation (e.g., patient self-report) and objective measures (e.g., urine toxicology testing).
The Addiction Severity Index (ASI) (McLellan, Kushner, Metzger, et al., 1992) is an instrument designed to assess the impact of a patient's addiction on his or her function. Although this instrument is typically used in research, it has been adapted for clinical use and illustrates the various aspects of a patient's life that should be assessed at each patient visit to determine the impact of active addiction or the benefits of abstinence. The ASI evaluates patient function in the areas of
- Drug use
- Alcohol use
- Psychiatric function
- Medical function
- Employment
- Social/family functioning
- Legal problems
In addition to patient self-report, urine testing can be a useful practice in monitoring patient progress in treatment. In some countries, urine testing is mandated as part of the treatment plan. A variety of substances can be detected in urine testing. Testing can occur for naturally occurring opioids (e.g., codeine, morphine) or synthetic or semi-synthetic opioids (e.g., oxycodone, methadone). Testing also can occur for benzodiazepines, cocaine, marijuana, or other drugs that are used and/or abused by the patient population. The period of detection of each of these substances varies with the laboratory technique that is used and the extent of drug use and can range from days to weeks.
References
McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992;9(3):199-213
Important Dates
NIDA International Forum
June 14–17, 2013
Online Registration Deadline:
May 6, 2013
FELLOWSHIPS
IAS/NIDA Fellowships
Application Deadline:
February 10, 2013
NIDA International Program Fellowships
Application Deadline:
April 1, 2013
Global Health Program for Fellows and Scholars
Application Deadlines: Vary
GRANTS
Brain Disorders in the Developing World: Research Across the Lifespan
(Non-AIDS)
R01 PAR-11-030and R21 PAR-11-031
Application deadline:
February 14, 2013
MEETINGS
American Association for the Advancement of Science
February 14–18, 2013
Boston, Massachusetts, USA
International Drug Abuse Research Society (IDARS)
April 15–19, 2013
Mexico City, Mexico
2013 International Conference on Global Health: Prevention and Treatment of Substance Abuse and HIV
April 17–19, 2013
Taipei, Taiwan
Yih-Ing Hser, Ph.D.